GlassScriptPhysician profile
Levi L Hubble
NPI 1891956587
$2,696.13
in general payments reported to CMS, 2019-2025
23 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $46.64 · 2021: $355 · 2022: $379 · 2023: $423 · 2024: $457 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Education: $37.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.01 |
| Education | $37.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,145.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.38 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $173.77 | 2025 | Rezdiffra |
| Allergan, INC. | $153.63 | 2019 | |
| Pfizer INC. | $129.04 | 2019-2022 | |
| Medtronic, INC. | $103.38 | 2023-2024 | Bravo, Gi Genius |
| Janssen Scientific Affairs, LLC | $89.82 | 2021 | |
| Janssen Biotech, INC. | $89.46 | 2019-2024 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.45 | 2019-2022 | |
| Daiichi Sankyo INC. | $71.54 | 2019 | |
| Ferring Pharmaceuticals INC. | $62.36 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $60.99 | 2021-2023 | Dificid |
| Gilead Sciences, INC. | $58.40 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $50.76 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $50.01 | 2023 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $35.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.02 | 2023 | Cyltezo |
| Lilly USA, LLC | $19.02 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $17.23 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.61 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2023 | Zeposia |
| Alfasigma USA, INC. | $14.43 | 2020 | |
| Cook Medical LLC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Hubble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.